ID905B - PROVISIONS CONTAIN STABLED GONADOTROPINS - Google Patents

PROVISIONS CONTAIN STABLED GONADOTROPINS

Info

Publication number
ID905B
ID905B IDP219492A ID922194A ID905B ID 905 B ID905 B ID 905B ID P219492 A IDP219492 A ID P219492A ID 922194 A ID922194 A ID 922194A ID 905 B ID905 B ID 905B
Authority
ID
Indonesia
Prior art keywords
preparations
lyophilized
dicarboxylic acid
disclosed
contain
Prior art date
Application number
IDP219492A
Other languages
Indonesian (id)
Inventor
Andreas Leo Johannes De Meere
Marinus Arie De Ruiter
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of ID905B publication Critical patent/ID905B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed are lyophilized gonadotropin containing preparations containing a dicarboxylic acid salt stabilizer. The particular proteins (e.g. LH, TSH, FSH, or HCG) are in admixture with, and at least partially capable of stabilization by, the particular stabilizer in lyophilized form. The preparations contain a sufficient amount of dicarboxylic acid salt to stabilize the protein in freeze-dried form for a desired time at a desired temperature. Typical dicarboxylic acid salts disclosed are the salts of citric, tartaric, and aspartic acids. The preparations preferably include a non-reducing disaccharide to increase the collapse temperature of the solution to be lyophilized. Methods of making the preparations in lyophilized form and the resulting injectable preparations are also disclosed. <IMAGE>
IDP219492A 1990-03-20 1992-01-31 PROVISIONS CONTAIN STABLED GONADOTROPINS ID905B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90200665 1990-03-20

Publications (1)

Publication Number Publication Date
ID905B true ID905B (en) 1996-09-10

Family

ID=8204967

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP219492A ID905B (en) 1990-03-20 1992-01-31 PROVISIONS CONTAIN STABLED GONADOTROPINS

Country Status (15)

Country Link
EP (1) EP0448146B1 (en)
JP (1) JP3031570B2 (en)
KR (1) KR100221123B1 (en)
AT (1) ATE107172T1 (en)
AU (1) AU631730B2 (en)
CA (1) CA2037884C (en)
DE (1) DE69102465T2 (en)
DK (1) DK0448146T3 (en)
ES (1) ES2057731T3 (en)
FI (1) FI101194B1 (en)
ID (1) ID905B (en)
IE (1) IE64738B1 (en)
NZ (1) NZ237458A (en)
PT (1) PT97074B (en)
ZA (1) ZA911659B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1250075B (en) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca PHARMACEUTICAL COMPOSITIONS CONTAINING GONADOTROPINE.
WO1994025005A1 (en) * 1993-04-28 1994-11-10 Akzo Nobel N.V. Lyospheres comprising gonadotropin
JP4165878B2 (en) * 1993-06-03 2008-10-15 株式会社林原生物化学研究所 Trehalose-releasing enzyme, its production method and use
US5556771A (en) * 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
PT814841E (en) * 1995-03-21 2002-03-28 Applied Research Systems HCG LIQUID FORMULATIONS
IL120202A (en) 1996-03-07 2001-03-19 Akzo Nobel Nv Container with freeze-dried vaccine components
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
IL140984A0 (en) * 1998-07-23 2002-02-10 Lilly Co Eli Fsh and fsh variant formulations, products and methods
JP2002541213A (en) 1999-04-13 2002-12-03 インヘール セラピューティック システムズ， インコーポレイテッド Pulmonary administration of dry powder formulations for the treatment of infertility
NZ525243A (en) 2000-10-31 2005-01-28 Pharma Mar S A lyophilised formulation comprising kahalalide F, a peptide isolated from a herbivorous marine species of mollusc, Elysia rufescens, to treat cancer
CA2433037C (en) 2000-12-28 2010-12-21 Takeda Chemical Industries, Ltd. Sustained-release preparation
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
DK1610822T4 (en) 2003-04-02 2019-01-14 Ares Trading Sa Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1638595B1 (en) 2003-06-20 2013-03-20 Ares Trading S.A. Freeze-dried fsh / lh formulations
DE10333317A1 (en) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulation for protein medicines without the addition of human serum albumin (HSA)
WO2005113147A2 (en) 2004-04-08 2005-12-01 Biomatrica, Inc. Integration of sample storage and sample management for life science
CN101495136A (en) * 2006-02-15 2009-07-29 英克隆系统公司 Antibody formulations
BRPI0818324B8 (en) * 2007-11-01 2021-05-25 Merck Serono Sa liquid formulation containing luteinizing hormone (LH) or a variant thereof, its use, its form of presentation, process for its preparation and pharmaceutical composition
CN101269215B (en) * 2008-05-15 2011-03-23 上海天伟生物制药有限公司 Glucoprotein incretion composition
EP2430195B1 (en) 2009-05-11 2019-01-23 Biomatrica, INC. Compositions and methods for biological sample storage
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
DK2635297T3 (en) 2010-11-05 2019-05-06 Baxalta GmbH A NEW VARIANT OF ANTIHEMOPHIL FACTOR VIII, WHICH HAS INCREASED SPECIFIC ACTIVITY
CN102293756A (en) * 2011-08-24 2011-12-28 蚌埠丰原涂山制药有限公司 Freeze-dried powder injection of menotropins and preparation method thereof
RS63930B1 (en) 2011-10-28 2023-02-28 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
DK2807188T3 (en) 2012-01-27 2019-10-07 Prothena Biosciences Ltd HUMANIZED ANTIBODIES RECOGNIZING ALPHA SYNUCLEIN
UA118441C2 (en) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Antibodies recognizing alpha-synuclein
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
ES2786373T3 (en) 2014-06-10 2020-10-09 Biomatrica Inc Platelet stabilization at room temperatures
KR20250047404A (en) 2015-12-08 2025-04-03 바이오매트리카 인코포레이티드 Reduction of erythrocyte sedimentation rate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932943A (en) * 1970-08-14 1976-01-20 E. I. Du Pont De Nemours And Company Method of preparation of lyophilized biological products
IT1057895B (en) * 1975-02-17 1982-03-30 Serono Lab HUMAN CHORIONIC GONADOTROPINE PARALLEL DESALINIZED TO INDUCE OUVULATION
DE3467706D1 (en) * 1983-04-28 1988-01-07 Armour Pharma Pharmaceutical preparation containing purified fibronectin
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration

Also Published As

Publication number Publication date
FI101194B (en) 1998-05-15
PT97074A (en) 1991-10-31
PT97074B (en) 1998-10-30
CA2037884A1 (en) 1991-09-21
FI101194B1 (en) 1998-05-15
ES2057731T3 (en) 1994-10-16
JPH04217630A (en) 1992-08-07
HK1002494A1 (en) 1998-08-28
CA2037884C (en) 2003-10-21
KR910016340A (en) 1991-11-05
AU7362391A (en) 1991-09-26
KR100221123B1 (en) 1999-09-15
DK0448146T3 (en) 1994-10-24
DE69102465T2 (en) 1995-03-02
ATE107172T1 (en) 1994-07-15
JP3031570B2 (en) 2000-04-10
NZ237458A (en) 1992-02-25
IE910732A1 (en) 1991-09-25
FI911309A0 (en) 1991-03-18
IE64738B1 (en) 1995-09-06
DE69102465D1 (en) 1994-07-21
AU631730B2 (en) 1992-12-03
EP0448146A1 (en) 1991-09-25
ZA911659B (en) 1991-12-24
EP0448146B1 (en) 1994-06-15
FI911309L (en) 1991-09-21

Similar Documents

Publication Publication Date Title
ID905B (en) PROVISIONS CONTAIN STABLED GONADOTROPINS
EP0607297A4 (en) Hormone analogs with multiple ctp extensions.
TR199800062A2 (en) Formulations containing liquid gonadotropin.
EP0355460A3 (en) Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization
CA2125855A1 (en) A stabilized pharmaceutical formulation comprising growth hormone and histidine
RU98100930A (en) LIQUID COMPOSITIONS CONTAINING GONADOTROPINE
DE3782737D1 (en) STABILIZATION OF GROWTH HORMONES.
ATE189608T1 (en) GONADOTROPIN CONTAINING PHARMACEUTICAL COMPOSITIONS WITH SUCROSE STABILIZER
IL82735A0 (en) Isolation of bioactive,monomeric growth hormone
US5384132A (en) Stabilized gonadotropin containing preparations
EP0726076A4 (en) Method of stabilizing protein c or activated protein c and stabilized composition
US5270057A (en) Stabilized gonadotropin containing preparations
DK149347C (en) PROCEDURE FOR PREPARING INSULIN PREPARATIONS WITH CRYSTALS WITH 2-ZN STRUCTURE
JPS54126723A (en) Preparation of specific hcg and specific anti-hcg-beta-subunit antibody
HUT47375A (en) Fungicide compositions containing /2-cyano-2-oximino-acetyl/-aminoacid derivatives as active components and process for producing the active components
EP0294668A3 (en) (2-cyano-2-oximinoacetyl)-amino acid derivatives
Slyvchuk et al. Stabilizing the gonadotropin activity with the use of organic compounds
KR950704494A (en) Vaccine against varicella-zoster virus (VZV) (VACCINES AGAINST VARICELLAZOSTER VIRUS (VZV))